{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T09:17:14Z","timestamp":1787995034272,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"General Project of Natural Science Foundation of Hainan Province","award":["Grant No.: 820MS128"],"award-info":[{"award-number":["Grant No.: 820MS128"]}]},{"DOI":"10.13039\/501100013142","name":"Key Research and Development Project of Hainan Province","doi-asserted-by":"publisher","award":["Grant No.: Qiong Wei Yi Hai(2021) No. 75"],"award-info":[{"award-number":["Grant No.: Qiong Wei Yi Hai(2021) No. 75"]}],"id":[{"id":"10.13039\/501100013142","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10067-026-08304-7","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:19:23Z","timestamp":1784546363000},"page":"5887-5897","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Post-marketing reporting patterns and disproportionality signals of mycophenolate mofetil: a pharmacovigilance study using the FAERS Database"],"prefix":"10.1007","volume":"45","author":[{"given":"Qiaofen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqiang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duopeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengna","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9962-1947","authenticated-orcid":false,"given":"Jiayao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5174-4778","authenticated-orcid":false,"given":"Zhou","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"1","key":"8304_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2024.151494","volume":"44","author":"D Massicotte-Azarniouch","year":"2024","unstructured":"Massicotte-Azarniouch D, Noel JA, Knoll GA (2024) Epidemiology of cancer in kidney transplant recipients. Semin Nephrol 44(1):151494","journal-title":"Semin Nephrol"},{"issue":"4","key":"8304_CR2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM et al (2021) Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 100(4):753\u2013779","journal-title":"Kidney Int"},{"issue":"1","key":"8304_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2023","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SCEULAR et al (2023) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83(1):15\u201329","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8304_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","volume":"6","author":"HJ Anders","year":"2020","unstructured":"Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C et al (2020) Lupus nephritis. Nat Rev Dis Prim 6(1):7","journal-title":"Nat Rev Dis Prim"},{"issue":"2","key":"8304_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.idc.2010.01.005","volume":"24","author":"JA Fishman","year":"2010","unstructured":"Fishman JA, Issa NC (2010) Infection in organ transplantation: risk factors and evolving patterns of infection. Infect Dis Clin North Am 24(2):273\u201383","journal-title":"Infect Dis Clin North Am"},{"issue":"18","key":"8304_CR6","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1056\/NEJMp2200089","volume":"386","author":"J Concato","year":"2022","unstructured":"Concato J, Corrigan-Curay J (2022) Real-world evidence - where are we now? N Engl J Med 386(18):1680\u20131682","journal-title":"N Engl J Med"},{"issue":"2","key":"8304_CR7","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1097\/JS9.0000000000002194","volume":"111","author":"H Liu","year":"2025","unstructured":"Liu H, Yang Q, Li Z, Yan S, Ming S (2025) Systematic analysis of sugammadex-related adverse drug reaction signals using FAERS database. Int J Surg 111(2):1988\u20131994","journal-title":"Int J Surg"},{"issue":"4","key":"8304_CR8","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3390\/cancers12040826","volume":"12","author":"S Cirmi","year":"2020","unstructured":"Cirmi S, El Abd A, Letinier L, Navarra M, Salvo F (2020) Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA Adverse Event Reporting System Database (FAERS). Cancers (Basel) 12(4):826","journal-title":"Cancers (Basel)"},{"issue":"3","key":"8304_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2016.26","volume":"10","author":"JM Banda","year":"2016","unstructured":"Banda JM, Evans L, Vanguri RS, Tatonetti NP, Ryan PB, Shah NH (2016) A curated and standardized adverse drug event resource to accelerate drug safety research. Sci Data 10(3):160026","journal-title":"Sci Data"},{"issue":"2","key":"8304_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S (1999) The medical dictionary for regulatory activities (MedDRA) - PubMed. Drug Saf 20(2):109\u201317","journal-title":"Drug Saf"},{"key":"8304_CR11","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-8124","author":"S Alexander","year":"2021","unstructured":"Alexander S, Swami U, Kaur A, Gao Y, Fatima M, Ginn MM et al (2021) Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease. Ann Transl Med. https:\/\/doi.org\/10.21037\/atm-20-8124","journal-title":"Ann Transl Med"},{"issue":"6","key":"8304_CR12","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/j.1399-0012.2008.00892.x","volume":"22","author":"S Bunnapradist","year":"2008","unstructured":"Bunnapradist S, Amb\u00fchl PM (2008) Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies. Clin Transplant 22(6):815\u2013821","journal-title":"Clin Transplant"},{"issue":"12","key":"8304_CR13","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.2215\/CJN.04410512","volume":"7","author":"S Karuthu","year":"2012","unstructured":"Karuthu S, Blumberg EA (2012) Common infections in kidney transplant recipients. Clin J Am Soc Nephrol 7(12):2058\u20132070","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"8304_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.54054","volume":"6","author":"FF Hou","year":"2023","unstructured":"Hou FF, Xie D, Wang J, Xu X, Yang X, Ai J et al (2023) Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial. JAMA Netw Open 6(2):e2254054","journal-title":"JAMA Netw Open"},{"issue":"5","key":"8304_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40262-013-0039-8","volume":"52","author":"AN Abd Rahman","year":"2013","unstructured":"Abd Rahman AN, Tett SE, Staatz CE (2013) Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease. Clin Pharmacokinet 52(5):303\u2013331","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"8304_CR16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/pds.815","volume":"12","author":"AC van Grootheest","year":"2003","unstructured":"van Grootheest AC, Groote JK, de Jong-van den Berg LT (2003) Intensive monitoring of new drugs based on first prescription signals from pharmacists: a pilot study. Pharmacoepidemiol Drug Saf 12(6):475\u201381","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"8304_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-005558","author":"N Matsuoka","year":"2025","unstructured":"Matsuoka N, Yajima N, Inoue E, Sato S, Ogawa S, Sumichika Y et al (2025) Safety of mycophenolate mofetil in systemic lupus erythematosus maintenance therapy: insights from the LUNA registry in a nationwide prospective cohort study. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2025-005558","journal-title":"RMD Open"},{"issue":"2","key":"8304_CR18","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10067-023-06820-4","volume":"43","author":"OA Abdelwahab","year":"2024","unstructured":"Abdelwahab OA, Mechi A, Gahlan S, Hamadein FE, Kadhim H, Ismail D et al (2024) Efficacy and safety of mycophenolate mofetil in patients with immune thrombocytopenic purpura: a systematic review and meta-analysis. Clin Rheumatol 43(2):621\u2013632","journal-title":"Clin Rheumatol"},{"key":"8304_CR19","unstructured":"Dodia P, Bermudez R (2025) Mohs micrographic surgery risks: carcinogenicity of immunosuppressive agents. In StatPearls\u00a0[Internet]. Treasure Island (FL): StatPearls Publishing.\u00a0Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK611984\/"},{"issue":"5","key":"8304_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124205","volume":"10","author":"MA Omair","year":"2015","unstructured":"Omair MA, Alahmadi A, Johnson SR (2015) Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review. PLoS ONE 10(5):e0124205","journal-title":"PLoS ONE"},{"issue":"4","key":"8304_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1399-3062.2009.00407.x","volume":"11","author":"ML Ritter","year":"2009","unstructured":"Ritter ML, Pirofski L (2009) Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis 11(4):290\u2013297","journal-title":"Transpl Infect Dis"},{"key":"8304_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106601","volume":"84","author":"Y Hu","year":"2020","unstructured":"Hu Y, Gong J, Zhang L, Li X, Li X, Zhao B et al (2020) Colitis following the use of immune checkpoint inhibitors: a real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. Int Immunopharmacol 84:106601","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"8304_CR23","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1097\/00007890-199911270-00012","volume":"68","author":"HU Meier-Kriesche","year":"1999","unstructured":"Meier-Kriesche HU, Friedman G, Jacobs M, Mulgaonkar S, Vaghela M, Kaplan B (1999) Infectious complications in geriatric renal transplant patients: comparison of two immunosuppressive protocols. Transplantation 68(10):1496\u20131502","journal-title":"Transplantation"},{"issue":"2","key":"8304_CR24","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.kint.2024.09.018","volume":"107","author":"S Caillard","year":"2025","unstructured":"Caillard S, Meyer N, Solis M, Bertrand D, Jaureguy M, Anglicheau D et al (2025) Insights from the BKEVER trial comparing everolimus versus mycophenolate mofetil for BK polyomavirus infection in kidney transplant recipients. Kidney Int 107(2):338\u2013347","journal-title":"Kidney Int"},{"issue":"12","key":"8304_CR25","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.2215\/CJN.01790215","volume":"10","author":"PE Cipp\u00e0","year":"2015","unstructured":"Cipp\u00e0 PE, Schiesser M, Ekberg H, van Gelder T, Mueller NJ, Cao CA et al (2015) Risk stratification for rejection and infection after kidney transplantation. Clin J Am Soc Nephrol 10(12):2213\u20132220","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"8304_CR26","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2165\/00002018-200124090-00002","volume":"24","author":"M Behrend","year":"2001","unstructured":"Behrend M (2001) Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 24(9):645\u2013663","journal-title":"Drug Saf"},{"issue":"7","key":"8304_CR27","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1016\/j.transproceed.2004.07.042","volume":"36","author":"YP Lu","year":"2004","unstructured":"Lu YP, Lin B, Liang MZ, Wang L, Nan F, Yu Q et al (2004) Correlation of mycophenolic acid pharmacokinetic parameters with side effects in Chinese kidney transplant recipients treated with mycophenolate mofetil. Transplant Proc 36(7):2079\u20132081","journal-title":"Transplant Proc"},{"key":"8304_CR28","doi-asserted-by":"publisher","first-page":"685","DOI":"10.12659\/AOT.889299","volume":"18","author":"A Kaltenborn","year":"2013","unstructured":"Kaltenborn A, Schrem H (2013) Mycophenolate mofetil in liver transplantation: a review. Ann Transplant 18:685\u2013696","journal-title":"Ann Transplant"},{"issue":"10","key":"8304_CR29","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/jnnp-2024-335400","volume":"96","author":"X Gong","year":"2025","unstructured":"Gong X, Liu Y, Ma Y, Yan B, An D, Guo Y et al (2025) Long-term maintenance of mycophenolate mofetil in anti-NMDA receptor encephalitis (LEARN): a multicentre, open-label, blinded-endpoint, randomised controlled trial. J Neurol Neurosurg Psychiatry 96(10):998\u20131007","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08304-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08304-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08304-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:35:04Z","timestamp":1787992504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08304-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8304"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08304-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study used publicly available, de-identified data from the U.S. FDA Adverse Event Reporting System. No direct interaction with human participants occurred. In accordance with institutional policy, ethics committee approval and individual informed consent were not required.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":3,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}}]}}